11.20.2018 Issue 428

Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Pfizer Announces Plans to Hike Price of 41 Drugs

Saturday, November 17

Pfizer on Friday announced plans to hike the list price of 41 drugs beginning Jan. 15, according to a FirstWord Pharma report.

Report: Patients Grapple with Synchronous Prescription Drug Price Hikes

Startup Deploys Outcomes-Based Model to Help Patients with Type 2 Diabetes

Study: Expensive Brand Drugs Driving up Prices

Survey: 42% See Value-Based Reimbursement Models Becoming Primary Model in Health Care

Consumers Concerned About Accuracy of Online Health Info

ICER Releases Report on Therapies for Long-term Prophylaxis HAE

CMS OKs Outcomes-Based Deals for Michigan Medicaid Program

ISPOR Seeking Nominees for 2019-20 President-Elect

Associate Director, Health Economics & Outcomes Research

Health Economics and Outcomes Associate Consultant

Research Data Assistant or Research Data Coordinator-PS8373

Research Associate III- Patient-Centered Research- Hammersmith

Industry Spotlight

Conferences Webinars
Applying DCE in Health Economics 2018
    November 21-23, Scotland, U.K.

The HTA Course – Trends & Opportunities - with Prof. Dr. Lieven Annemans
    November 22, Brussels, Belgium

ESMO Asia 2018 Congress
    November 23-25, Singapore

18th Annual Rx Drug Pricing Boot Camp
    November 27-30, Philadelphia, Pennsylvania

Bio/Pharma Summit on Nurse Educator Programs
    November 27, Philadelphia, Pennsylvania

Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures
    November 27

New Requirements for Selling Devices in the European Union
    December 3

Intelligent Approaches to Transform Value and Access
    December 12

Managing Challenging Long-term Services and Supports Patients to Improve Care and Reduce Costs
    December 13

Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

HTA in Europe: Key Success Factors for Positive HTA Recommendations

Paying for Digital Health: Payer Insights

Benchmarking Pharma’s MSL Capabilities

Transitioning Payment Models: Fee-for-Service to Value-Based Care

How Health Plans and Providers Can Collaborate to Improve Care Transitions and Reduce Hospital Readmissions

Generating Consensus and Trust for Quality Measurement to Support Value-Based Care

An Evidence-Based Approach to Hiring: Leaders, Physicians, Nurses, and Front Line Staff

Big Data in Pharmaceuticals: Big Opportunities or Big Challenges – or Both?

AHIP Executive Roundtable Discussion Summary

Special Thanks to Our Partners:
Evidera   HealthCore     University of FL  Xcenda   OM1
Parexel   Jefferson   Dymaxium   Precision Xtract    Pharmerit
    eMax Health   Sciformix   Evidence Partners   
ICON    Truven    
Share this newsletter on social media:

Email Twitter Facebook LinkedIn